AstraZeneca R&D - Articles and news items


European Commission approves Fluenz Tetra for the prevention of seasonal influenza in children

Industry news / 6 December 2013 / AstraZeneca

Fluenz Tetra is a nasally administered four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age…

Pills Powder

Evolution of drug metabolism and pharmacokinetics in drug discovery and development

Drug Discovery, Issue 3 2012 / 10 July 2012 / Dr. Dermot McGinnity, Innovative Medicines, AstraZeneca R&D

Drug Metabolism and Pharmacokinetics (DMPK) is a scientific discipline once primarily associated with safety evaluation in drug development that has, in the last two decades, become a core discipline within drug discovery, development and even post-marketing. Approximately 20 years ago, sub-optimal DMPK properties were recognised as a contributor to the failure of potential new therapies in early clinical trials and this precipitated the realignment of DMPK within discovery to assist in selecting optimal drug candidates to enter clinical trials. In addition to adequate potency against the target protein and an acceptable safety profile, a balance of optimised PK parameters and minimised drug-drug interaction (DDI) potential maximises the chance of a candidate drug becoming a successful therapy…

In-Depth Focus: Mass Spectrometry

In-depth focus – Mass Spectrometry

Chromatography, Issue 2 2012, Supplements / 25 April 2012 / Ana Rita Angelino, Min Yang, Tasso Miliotis, Constanze Hilgendorf, Anthony Bristow, George McLeod, Detlev Hochmuth, Alessandro Baldi, Gary Harland

Mass spectrometry in drug discovery – Proteomics, small molecules and metablomics.
Quantification of membrane drug transporters and application in drug discovery and development.
Mass spectrometry leaders roundtable.

A new approach to ion channel hit identification

Issue 4 2005, Past issues / 11 November 2005 / Martin J. Main, Karen Jones, Biological Chemistry, AstraZeneca R&D, UK, Mats A. Svensson, Dirk Weigelt and Markus Haeberlein, Chemistry, AstraZeneca R&D, Sweden

Advances in assay technology are driving an exciting new era in ion channel drug discovery. Here, we present a case study describing the use of computational chemistry and focussed library screening to drive rapid hit identification.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...